Account
Insider Insights
20.04.2022
Access to cancer drugs

According to the report, the financing of cancer drugs in Spain is “very high” with 90% of oncol...

Read more
Insider Insights
24.03.2022
Manufacturer paybacks of E1 billion in relation to

Consequently, paybacks from pharmaceutical manufacturers of around €1 billion will be due from pha...

Read more
Insider Insights
24.03.2022
“First of its kind” MAA leads to NICE approval

The draft final guidance reverses previous guidance issued in November 2021 rejecting the drug for r...

Read more
Insider Insights
21.03.2022
Revise payment percentage paid

The DHSC is proposing to increase the statutory scheme payment percentage for 2022 from 10.9% to 14....

Read more
Insider Insights
17.03.2022
Germany: Proposed new pharmaceutical cost

The proposals are set out in the draft Statutory Health Insurance Financial Stabilisation Bill which...

Read more
Insider Insights
03.03.2022
Ensuring patients have access to orphan drugs

According to the pharmaceutical industry association, Farmaindustria, 40% of orphan drugs approved i...

Read more
Insider Insights
03.03.2022
NICE recommends routine use of Zejula

The National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s Zej...

Read more
Insider Insights
01.03.2022
Spotlight on access to orphan drugs

The Ministry of Health hhas published a report on the “evolution of funding and fixing of the pric...

Read more
Insider Insights
16.02.2022
AIFA announces reimbursement of oral SMA treatment

The Italian Medicines Agency (AIFA) has announced that Roche’s Evyrsdi (risdiplam) is reimbursed w...

Read more
Insider Insights
07.02.2022
NHS England announces access deal for Libmeldy

The news comes after the health service negotiated a “significant confidential discount” to the ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.